Keen Vision Acquisition CORP

Keen Vision Acquisition Corporation announced its securities will be suspended and delisted from Nasdaq due to non-compliance with listing rules, including the deadline for business combinations and minimum public float requirements.

Keen Vision Acquisition Corporation has issued a $120,000 promissory note to its sponsor to extend the deadline for completing a business combination to July 27, 2026.

Keen Vision Acquisition Corporation has amended its letter of intent with Medera Inc., extending the deadline to negotiate and execute a replacement merger agreement to April 30, 2026.

Keen Vision Acquisition Corporation terminates prior merger agreement with Medera Inc. and enters new Letter of Intent for a revised business combination with Novoheart Group Limited.

Keen Vision Acquisition Corporation secured shareholder approval to extend its business combination deadline to July 27, 2026, but saw 3.78 million shares redeemed.

Keen Vision Acquisition Corporation secured a $144,670.38 promissory note from its sponsor to extend its business combination deadline to January 27, 2026.

Keen Vision Acquisition Corporation reports Q1 2026 results while continuing to pursue a business combination with Medera Inc. and Novoheart Group Limited.

Keen Vision Acquisition Corporation reports a significant decline in Trust Account assets and a working capital deficit, raising substantial doubt about its ability to continue as a going concern without completing its proposed merger by November 27, 2025.

Keen Vision Acquisition Corporation reports a significant decline in cash and net income, facing going concern doubts as it extends its deadline to complete a merger with biopharmaceutical company Medera Inc.

Keen Vision Acquisition Corporation (KVAC) reports a net income of $568,171 for the quarter ended March 31, 2025, while continuing efforts to finalize a business combination, extending the deadline to May 27, 2025.

Keen Vision Acquisition Corporation reported a net income of $6.6 million for the nine months ended September 30, 2024, while progressing with its merger plans with Medera Inc.

Keen Vision Acquisition Corporation reported a net income of $5.04 million for the six months ended June 30, 2024, primarily driven by investment income from its trust account, while actively pursuing a business combination.

Keen Vision Acquisition Corporation reports a significant reduction in its trust account balance due to redemptions and a going concern warning, while pursuing a new, smaller business combination target.

Keen Vision Acquisition Corporation's 10-K filing reveals a net income for 2024 but raises concerns about its ability to continue as a going concern if a business combination is not completed by March 27, 2025.

Keen Vision Acquisition Corporation's 10-K filing outlines its financial status, IPO details, and strategy for identifying a business combination target in biotech, consumer goods, or agriculture.

Mederas Novoheart and Curi Bio have partnered to integrate their technologies, aiming to accelerate and improve the efficiency of human-based cardiac drug screening.

Medera's Novoheart has launched CTScreen v1.5, an advanced automated cardiac screening platform, which has been adopted by AstraZeneca to enhance human heart-based drug testing.

Medera and the Cardiovascular Disease National Collaborative Enterprise (CADENCE) have initiated Asia's first cardiac gene therapy clinical trial for heart failure in Singapore, marking a significant step in global cardiovascular research.

Medera's Novoheart subsidiary leverages AI and machine learning to enhance drug screening with human mini-Heart technology, potentially reducing costs and improving clinical trial success rates.

Medera's gene therapy subsidiary, Sardocor Corp., has completed Cohort A and initiated dosing in Cohort B of its MUSIC-HFpEF Phase 1/2a clinical trial evaluating SRD-002 for Heart Failure with Preserved Ejection Fraction (HFpEF).

Keen Vision Acquisition Corporation (KVAC) and Medera Inc. have entered into a definitive merger agreement, aiming to list Medera on NASDAQ with an implied initial enterprise value of approximately $622.6 million.

Keen Vision Acquisition Corporation is holding an extraordinary general meeting on July 21, 2026, to vote on proposals to extend its deadline for completing a business combination and amend its governing documents.

Keen Vision Acquisition Corporation filed definitive additional materials to correct a clerical error regarding its proposed quarterly extension fee for its trust account, setting it at $120,000 for each three-month extension.

Keen Vision Acquisition Corporation is seeking shareholder approval to extend its business combination deadline to July 27, 2026, to avoid liquidation.

Keen Vision Acquisition Corporation (KVAC) is soliciting shareholder votes to extend its business combination deadline from July 27, 2025, to January 27, 2026, to avoid liquidation and continue its search for a suitable acquisition target.

Keen Vision Acquisition Corporation adjourned its annual general meeting to October 25, 2024, to allow shareholders more time to vote on proposals.

Keen Vision Acquisition Corporation is seeking shareholder approval to amend its trust agreement and charter to extend the deadline for completing a business combination and reduce the monthly extension fee.

Mizuho Financial Group, Inc. has filed a Schedule 13G, reporting beneficial ownership of Keen Vision Acquisition Corp. common shares.

Karpus Management, Inc. has filed an amendment to its Schedule 13G, reporting a 3.18% beneficial ownership stake in Keen Vision Acquisition Corp.

Karpus Management, Inc. reports a 13.37% beneficial ownership stake in Keen Vision Acquisition Corp. common stock as of September 30, 2025.

W. R. Berkley Corporation and its subsidiary Berkley Insurance Company have reported a 7.7% beneficial ownership stake in Keen Vision Acquisition Corporation's Ordinary Shares.

Wolverine Asset Management and related entities have reported a 3.22% beneficial ownership stake in Keen Vision Acquisition Corp.'s Ordinary Shares.

Mizuho Financial Group, Inc. has disclosed a 9.0% beneficial ownership stake in Keen Vision Acquisition Corporation, holding 973,800 common shares.